These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 35976170)

  • 1. Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study.
    Kawsar A; Edwards C; Patel P; Heywood RM; Gupta A; Mann J; Harland C; Heelan K; Larkin J; Lorigan P; Harwood CA; Matin RN; Fearfield L
    Br J Dermatol; 2022 Dec; 187(6):981-987. PubMed ID: 35976170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study.
    Espi M; Teuma C; Novel-Catin E; Maillet D; Souquet PJ; Dalle S; Koppe L; Fouque D
    Eur J Cancer; 2021 Apr; 147():29-39. PubMed ID: 33607383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management.
    Lopez AT; Geskin L
    Oncologist; 2018 Oct; 23(10):1119-1126. PubMed ID: 30018132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors.
    Gault A; Anderson AE; Plummer R; Stewart C; Pratt AG; Rajan N
    Br J Dermatol; 2021 Aug; 185(2):263-271. PubMed ID: 33393076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology Centers.
    Sadik CD; Langan EA; Gutzmer R; Fleischer MI; Loquai C; Reinhardt L; Meier F; Göppner D; Herbst RA; Zillikens D; Terheyden P
    Front Immunol; 2020; 11():588582. PubMed ID: 33708189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
    Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
    J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors.
    Lopez AT; Khanna T; Antonov N; Audrey-Bayan C; Geskin L
    Int J Dermatol; 2018 Jun; 57(6):664-669. PubMed ID: 29630716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIM
    Curti B; Daniels GA; McDermott DF; Clark JI; Kaufman HL; Logan TF; Singh J; Kaur M; Luna TL; Gregory N; Morse MA; Wong MKK; Dutcher JP
    J Immunother Cancer; 2017 Dec; 5(1):102. PubMed ID: 29254506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case report of steroid-refractory bullous pemphigoid induced by immune checkpoint inhibitor therapy.
    Guan S; Zhang L; Zhang J; Song W; Zhong D
    Front Immunol; 2022; 13():1068978. PubMed ID: 36685586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors.
    Ornstein MC; Calabrese C; Wood LS; Kirchner E; Profusek P; Allman KD; Martin A; Kontzias A; Grivas P; Garcia JA; Calabrese LH; Rini BI
    Clin Genitourin Cancer; 2019 Jun; 17(3):177-182. PubMed ID: 30824360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous manifestations induced by check point inhibitors in 120 melanoma patients-The European MelSkinTox study.
    L'Orphelin JM; Cassecuel J; Kandolf L; Harwood CA; Tookey P; Junejo MH; Hogan S; Lebbé C; Appalla Z; Kränke TM; Pellacani G; Cerasuolo D; Dujovic B; Del Marmol V; Forschner A; Garbe C; Bataille V; Ressler JM; Sollena P; Dompmartin A; Peris K; Dreno B;
    J Eur Acad Dermatol Venereol; 2023 Apr; ():. PubMed ID: 37042810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma.
    Pepys J; Stoff R; Ramon-Gonen R; Ben-Betzalel G; Grynberg S; Frommer RS; Schachter J; Asher N; Taliansky A; Nikitin V; Dori A; Shelly S
    Neurology; 2023 Dec; 101(24):e2472-e2482. PubMed ID: 37652699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bullous Pemphigoid Associated with Anti-programmed Cell Death Protein 1 and Anti-programmed Cell Death Ligand 1 Therapy: A Review of the Literature.
    Tsiogka A; Bauer JW; Patsatsi A
    Acta Derm Venereol; 2021 Jan; 101(1):adv00377. PubMed ID: 33426566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study.
    Olsson Ladjevardi C; Koliadi A; Rydén V; Inan El-Naggar A; Digkas E; Valachis A; Ullenhag GJ
    Cancer Med; 2023 Jun; 12(12):13217-13224. PubMed ID: 37132258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer: A Systematic Review.
    Asdourian MS; Shah N; Jacoby TV; Reynolds KL; Chen ST
    JAMA Dermatol; 2022 Aug; 158(8):933-941. PubMed ID: 35612829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1.
    Naidoo J; Schindler K; Querfeld C; Busam K; Cunningham J; Page DB; Postow MA; Weinstein A; Lucas AS; Ciccolini KT; Quigley EA; Lesokhin AM; Paik PK; Chaft JE; Segal NH; D'Angelo SP; Dickson MA; Wolchok JD; Lacouture ME
    Cancer Immunol Res; 2016 May; 4(5):383-9. PubMed ID: 26928461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy.
    Ghisoni E; Wicky A; Bouchaab H; Imbimbo M; Delyon J; Gautron Moura B; Gérard CL; Latifyan S; Özdemir BC; Caikovski M; Pradervand S; Tavazzi E; Gatta R; Marandino L; Valabrega G; Aglietta M; Obeid M; Homicsko K; Mederos Alfonso NN; Zimmermann S; Coukos G; Peters S; Cuendet MA; Di Maio M; Michielin O
    Eur J Cancer; 2021 May; 149():153-164. PubMed ID: 33865201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generalized morphoea in the setting of combined immune checkpoint inhibitor therapy for metastatic melanoma: A case report.
    Langan EA; Budner K; Zillikens D; Terheyden P
    Medicine (Baltimore); 2021 Apr; 100(16):e25513. PubMed ID: 33879687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk Factors for the Development of Bullous Pemphigoid in US Patients Receiving Immune Checkpoint Inhibitors.
    Said JT; Liu M; Talia J; Singer SB; Semenov YR; Wei EX; Mostaghimi A; Nelson CA; Giobbie-Hurder A; LeBoeuf NR
    JAMA Dermatol; 2022 May; 158(5):552-557. PubMed ID: 35416925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutaneous metastases at the sites of pembrolizumab-induced bullous pemphigoid lesions in a patient with melanoma.
    Ványai B; Chien YC; Beke L; Szabó IL; Péter Z; Steuer-Hajdu K; Várvölgyi T; Méhes G; Emri G
    Immunotherapy; 2022 Dec; 14(17):1377-1382. PubMed ID: 36475303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.